CNC · NYQ · Healthcare
Centene Corporation
Also onShortfallConsensus DriftCrosscheck
Implied value per share
USD 119.74
Market price
USD 65.11
Implied upside
+83.9%
5-year forecast · Perpetuity growth terminal value · Mid-year discounting · Base case
Current EV/EBITDA of 31.2x sits outside a defensible 3-20x band, so the exit multiple is capped at 20.0x. A multiple that far out usually means EBITDA is the wrong denominator for this business.
Value Per Share
Same forecast, different terminal treatment. Percentages vs price.
Forecast Cashflows
Reporting currency (USD). Outflows negative.
| Line | FY26 | FY27 | FY28 | FY29 | FY30 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | USD 215.1bn | USD 237.6bn | USD 262.5bn | USD 289.9bn | USD 320.2bn | +10.5% |
| EBIT | USD 3.5bn | USD 3.9bn | USD 4.3bn | USD 4.8bn | USD 5.2bn | +10.5% |
| NOPAT | USD 2.8bn | USD 3.1bn | USD 3.4bn | USD 3.8bn | USD 4.1bn | +10.5% |
| Add depreciation & amortisation | USD 1.7bn | USD 1.9bn | USD 2.1bn | USD 2.4bn | USD 2.6bn | +10.5% |
| Less capital expenditure | USD -2.2bn | USD -2.4bn | USD -2.6bn | USD -2.9bn | USD -3.2bn | +10.5% |
| Less increase in working capital | USD 2.0bn | USD 2.2bn | USD 2.4bn | USD 2.6bn | USD 2.9bn | -10.5% |
| Free cashflow to firm | USD 4.3bn | USD 4.8bn | USD 5.3bn | USD 5.8bn | USD 6.4bn | +10.5% |
| Discount factor | 0.9605 | 0.8862 | 0.8177 | 0.7544 | 0.6961 | - |
| Present value | USD 4.2bn | USD 4.2bn | USD 4.3bn | USD 4.4bn | USD 4.5bn | +1.9% |
| Present Value Of The Forecast | USD 21.6bn | |||||
Discount Rate
Source shown per component. All overridable above.
| Risk-free rate | 5.00% | US 10-year Treasury (^TNX) |
| Equity risk premium | 5.50% | Market assumption |
| Beta | 1.071 | Reported 1.106, pulled toward 1.0 (Blume) |
| Cost of equity | 10.89% | Risk-free + beta x equity risk premium |
| Cost of debt | 5.00% | Floored at the risk-free rate (implied cost of debt was lower) |
| Market capitalisation | USD 32.2bn | 63.9% of capital |
| Total debt | USD 18.2bn | 36.1% of capital, book value as a proxy |
| Tax rate | 21.0% | Effective, capped at statutory |
| WACC | 8.38% | E/V x Re + D/V x Rd x (1 - t) |
Terminal Value
Perpetuity growth is intrinsic. The exit multiple defaults to the company's current EV/EBITDA, so it answers a different question - what the shares are worth if today's rating holds and EBITDA grows as forecast.
Perpetuity growth at 2.50%
62% of EV
- Forecast FCFF, final year
- USD 6.4bn
- Capex at depreciation, working capital in reinvestment
- USD 4.1bn
- Less reinvestment at g/ROIC (29.8% of NOPAT)
- USD -1.2bn
- Capitalised
- USD 2.9bn
- ROIC (WACC floor)
- 8.4%
- Terminal value, undiscounted
- USD 50.7bn
- Terminal value, discounted
- USD 35.3bn
- Enterprise value
- USD 56.9bn
- Less net debt
- USD -2.2bn
- Equity value
- USD 59.0bn
Exit at 20.0x EBITDA
83% of EV
- Terminal value, undiscounted
- USD 156.9bn
- Terminal value, discounted
- USD 109.2bn
- Enterprise value
- USD 130.8bn
- Less net debt
- USD -2.2bn
- Equity value
- USD 133.0bn
Spread between methods: 77%.
Sensitivity
Value per share (USD) by discount rate and long-run growth.
| Long-run growth | |||||
|---|---|---|---|---|---|
| Discount rate | 1.50% | 2.00% | 2.50% | 3.00% | 3.50% |
| 6.38% | 151.52 | 152.01 | 152.51 | 153.01 | 153.51 |
| 7.38% | 133.12 | 133.53 | 133.94 | 134.36 | 134.77 |
| 8.38% | 119.05 | 119.40 | 119.74 | 120.09 | 120.44 |
| 9.38% | 107.93 | 108.23 | 108.53 | 108.82 | 109.12 |
| 10.38% | 98.91 | 99.17 | 99.43 | 99.69 | 99.95 |
Outlined: this model. Green text: above today's price of 65.11. Shading: distance from this model's own value.
Priced In
What each input would have to be to justify the current price, one at a time.
| Input | Model | Implied | Gap |
|---|---|---|---|
| Revenue growth, every year | 10.5% | -0.2% | -10.6pp |
| EBIT margin | 1.6% | 0.7% | -0.9pp |
| Discount rate | 8.4% | 17.2% | +8.8pp |
Live formulas, not pasted numbers - edit a driver and the workbook reprices.
Yahoo Finance and RBA data. General information, not advice. Methodology.